LCTX

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for BioTime, Inc. (Note: The request metadata listed "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.) for the period ended March 31, 1999. BioTime is a development-stage biomedical company focused on synthetic plasma expanders and organ preservation solutions. A significant milestone occurred on March 31, 1999, when the company received FDA approval to market its first product, Hextend.

Key Financial Metrics

Revenue Composition: Q1 1999 revenue consisted of $187,500 in amortization of deferred license fees and $250,000 recognized for achieving a specific milestone under the Abbott Laboratories license agreement.

Material Changes vs. Prior Period

• Liquidity Surge: Cash and cash equivalents increased from $2,429,014 at December 31, 1998, to $8,609,463 at March 31, 1999. This was driven primarily by a subscription rights offering completed on March 9, 1999, which raised $7,328,626 (net of offering costs) through the sale of 751,654 common shares.
• Revenue Growth: Revenue increased 250% year-over-year (from $125,000 to $437,500) due to the recognition of a $250,000 milestone payment from Abbott Laboratories.
• Expense Reduction: Research and development (R&D) expenses decreased by approximately 16% (from $878,422 to $739,484) due to a shift in focus from basic laboratory research to regulatory applications and clinical trial planning. Conversely, General and Administrative (G&A) expenses increased by approximately 31% (from $390,904 to $513,450) due to increased personnel costs.
• Regulatory Milestone: The company transitioned from a pure R&D phase to a commercialization phase with the FDA approval of Hextend on the last day of the quarter.

Outlook, Risks, and Management Commentary

• Commercialization Strategy: BioTime has granted Abbott Laboratories an exclusive license to manufacture and sell Hextend in the U.S. and Canada. Abbott is obligated to pay license fees based on milestones and royalties based on sales (5% to 36% depending on sales volume). BioTime retains rights to market the product globally outside the U.S. and Canada.
• Future Funding: Management expects current cash reserves to fund operations for more than 12 months. However, additional funding will likely be required for future clinical trials of new products (PentaLyte, HetaCool) and global expansion. Future financing may come from licensing fees, royalties, or additional equity/debt sales, which could dilute shareholders.
• Risks:
  • Development Stage: The company has incurred cumulative losses of $17.5 million since inception and has no history of profitable operations.
  • Regulatory Dependence: Future success depends on obtaining regulatory approvals for new products and uses, which are uncertain and costly.
  • Year 2000 Compliance: While internal systems are deemed compliant, the company relies on third-party contractors and Abbott for manufacturing and data analysis. If these partners face Year 2000 issues, product distribution could be adversely affected.
  • Market Competition: The company faces competition from other manufacturers of blood volume expanders and organ preservation solutions.

Investor Verification Checklist

• Verify the terms of the exclusive license agreement with Abbott Laboratories, specifically the royalty tiers and milestone triggers.
• Confirm the timeline and budget for upcoming clinical trials for PentaLyte and HetaCool, as these will drive future R&D expenses.
• Monitor the progress of international licensing negotiations, as this is the primary strategy for global revenue generation outside the Abbott territory.
• Review the company's cash burn rate to ensure the $8.6 million cash balance is sufficient to reach the next major revenue milestone or financing event.
• Assess the potential dilution impact of future equity offerings required to fund continued development.